Targets › TRPC6
1 program from 1 company in 1 trial: 1 Phase 1; Immunology; next expected readout Feb 2027.
Non-selective, calcium-permeable cation channel. Mediates calcium entry following G(q)-coupled receptor or receptor tyrosine kinase activation, which triggers phospholipase C (PLC)-mediated hydrolysis of phosphatidylinositides and production of diacylglycerol (DAG) that directly activates TRPC6. (UniProt, Q9Y210)
Open in Phaseline: the race on TRPC6, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Applied Biology | Hyperforin TRPC channel activator and plant extract with anti-inflammatory properties | TRPC6 | Phase 1 | Chemotherapy Induced Alopecia | Feb 2027 |
Chemotherapy Induced Alopecia (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.